{"filing":{"accession_number":"0001193125-26-396065","cik":"0001520262","ticker":"ALKS","company_name":"Alkermes plc.","form":"8-K","filing_date":"2026-09-21","report_date":"2026-09-21","primary_document":"alks-20260921.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1520262/000119312526396065/alks-20260921.htm"},"events":[{"id":33860,"run_id":31163,"accession_number":"0001193125-26-396065","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Alkermes disclosed positive Phase 1b clinical trial results for ALKS 7290, an investigational orexin 2 receptor agonist for ADHD, demonstrating clinically meaningful improvements in ADHD symptoms on validated scales (AISRS and CGI-S) and good tolerability. The company is advancing the program to Phase 2 trials, representing a material clinical development milestone that affects investor assessment of the company's pipeline value and strategic direction in neuroscience.","company_name":"Alkermes plc.","ticker":"ALKS","filing_date":"2026-09-21","form":"8-K","submitted_at":null,"items":[{"id":37425,"accession_number":"0001193125-26-396065","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Alkermes disclosed positive Phase 1b clinical trial results for ALKS 7290, demonstrating proof-of-concept for an investigational ADHD treatment. The press release reports clinically meaningful improvements in ADHD symptoms on validated scales (AISRS and CGI-S) and good tolerability across dose groups, with a Phase 2 study currently enrolling. This represents a material operational/clinical milestone in the company's drug development pipeline that would affect investor assessment of the company's pipeline value and strategic direction in neuroscience.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T11:11:57.483373+00:00","company_name":"","ticker":null,"filing_date":""},{"id":37426,"accession_number":"0001193125-26-396065","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Alkermes announced positive Phase 1b proof-of-concept results for ALKS 7290, a novel orexin 2 receptor agonist in development for ADHD. The disclosure demonstrates clinically meaningful improvements in ADHD symptoms and supports advancement to Phase 2 trials. This is a material clinical development milestone for a biopharmaceutical company's pipeline candidate, representing significant progress in a key therapeutic program, though it does not fit the specific categories of earnings release, M\u0026A activity, or other defined event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T11:11:57.483373+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37425,"accession_number":"0001193125-26-396065","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Alkermes disclosed positive Phase 1b clinical trial results for ALKS 7290, demonstrating proof-of-concept for an investigational ADHD treatment. The press release reports clinically meaningful improvements in ADHD symptoms on validated scales (AISRS and CGI-S) and good tolerability across dose groups, with a Phase 2 study currently enrolling. This represents a material operational/clinical milestone in the company's drug development pipeline that would affect investor assessment of the company's pipeline value and strategic direction in neuroscience.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T11:11:57.483373+00:00","company_name":"Alkermes plc.","ticker":"ALKS","filing_date":"2026-09-21"},{"id":37426,"accession_number":"0001193125-26-396065","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Alkermes announced positive Phase 1b proof-of-concept results for ALKS 7290, a novel orexin 2 receptor agonist in development for ADHD. The disclosure demonstrates clinically meaningful improvements in ADHD symptoms and supports advancement to Phase 2 trials. This is a material clinical development milestone for a biopharmaceutical company's pipeline candidate, representing significant progress in a key therapeutic program, though it does not fit the specific categories of earnings release, M\u0026A activity, or other defined event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T11:11:57.483373+00:00","company_name":"Alkermes plc.","ticker":"ALKS","filing_date":"2026-09-21"}]}